Identification

Name
Ibutilide
Accession Number
DB00308  (APRD01025)
Type
Small Molecule
Groups
Approved
Description

Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.

Structure
Thumb
Synonyms
  • Ibutilid
  • Ibutilida
  • Ibutilide
  • Ibutilidum
  • N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
External IDs
U 70226 E
Product Ingredients
IngredientUNIICASInChI Key
Ibutilide fumarate9L5X4M5L6I 122647-32-9PCIOHQNIRPWFMV-WXXKFALUSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CorvertSolution0.1 mgIntravenousPfizer2000-11-28Not applicableCanada
CorvertInjection, solution.1 mg/mLIntravenousPharmacia & Upjohn Inc1995-12-28Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ibutilide FumarateInjection, solution.1 mg/mLIntravenousGenera Medix Inc.2010-01-12Not applicableUs
Ibutilide FumarateInjection, solution.1 mg/mLIntravenousMylan Institutional2010-01-11Not applicableUs
Categories
UNII
2436VX1U9B
CAS number
122647-31-8
Weight
Average: 384.576
Monoisotopic: 384.244663718
Chemical Formula
C20H36N2O3S
InChI Key
ALOBUEHUHMBRLE-UHFFFAOYSA-N
InChI
InChI=1S/C20H36N2O3S/c1-4-6-7-8-9-16-22(5-2)17-10-11-20(23)18-12-14-19(15-13-18)21-26(3,24)25/h12-15,20-21,23H,4-11,16-17H2,1-3H3
IUPAC Name
N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide
SMILES
CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1

Pharmacology

Indication

Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.

Structured Indications
Pharmacodynamics

Ibutilide prolongs the action potential duration and increases both atrial and ventricular refractoriness in vivo, i.e., class III electrophysiologic effects. Voltage clamp studies indicate that ibutilide, at nanomolar concentrations, delays repolarization by activation of a slow, inward current (predominantly sodium), rather than by blocking outward potassium currents, which is the mechanism by which most other class III antiarrhythmics act.

Mechanism of action

Ibutilide is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca2+ channel blockers and potent inhibition of the cardiac rapid delayed rectifier K+ current, by binding within potassium channel pores. In other words, Ibutilide binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
activator
Human
AVoltage-dependent L-type calcium channel subunit beta-1
activator
Human
APotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UVoltage-dependent calcium channel subunit alpha-2/delta-1
activator
Human
UVoltage-dependent calcium channel gamma-1 subunit
activator
Human
UPotassium channel subfamily K member 1
inhibitor
Human
UPotassium channel subfamily K member 6
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 6
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 7
inhibitor
Human
UATP-sensitive inward rectifier potassium channel 11
inhibitor
Human
Absorption

Rapid after intravenous injection

Volume of distribution
  • 11 L/kg
Protein binding

40%

Metabolism

Primarily hepatic. Eight metabolites of ibutilide were detected in metabolic profiling of urine. These metabolites are thought to be formed primarily by o-oxidation followed by sequential b-oxidation of the heptyl side chain of ibutilide. Of the eight metabolites, only the o-hydroxy metabolite possesses class III electrophysiologic properties similar to that of ibutilide in an in vitro isolated rabbit myocardium model.

Route of elimination

In healthy male volunteers, about 82% of a 0.01 mg/kg dose of [14C] ibutilide fumarate was excreted in the urine (about 7% of the dose as unchanged ibutilide) and the remainder (about 19%) was recovered in the feces.

Half life

6 hours (ranges from 2-12 hours)

Clearance
  • 29 mL/min/kg
Toxicity

Acute overdose in animals results in CNS toxicity; notably, CNS depression, rapid gasping breathing, and convulsions. The intravenous median lethal dose in the rat was more than 50 mg/kg which is, on a mg/m2 basis, at least 250 times the maximum recommended human dose.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ibutilide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Ibutilide.Approved
AmiodaroneIbutilide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Ibutilide.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Ibutilide.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Ibutilide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
Arsenic trioxideIbutilide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIbutilide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIbutilide may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ibutilide.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Ibutilide.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Ibutilide.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
BuserelinBuserelin may increase the QTc-prolonging activities of Ibutilide.Approved
CeritinibCeritinib may increase the QTc-prolonging activities of Ibutilide.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
CisaprideIbutilide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Ibutilide.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Ibutilide.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Ibutilide.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Ibutilide.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Ibutilide.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Ibutilide.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Ibutilide.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Ibutilide.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Ibutilide.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Ibutilide.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Ibutilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Ibutilide.Approved
DomperidoneIbutilide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Ibutilide.Approved
DronedaroneIbutilide may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
EliglustatIbutilide may increase the QTc-prolonging activities of Eliglustat.Approved
EribulinEribulin may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
EscitalopramIbutilide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Ibutilide.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Ibutilide.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Ibutilide.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Ibutilide.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Ibutilide.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Ibutilide.Approved
FluoxetineIbutilide may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolIbutilide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ibutilide.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ibutilide.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Ibutilide.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Ibutilide.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Ibutilide.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Ibutilide.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Ibutilide.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
IloperidoneIbutilide may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Ibutilide.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ibutilide.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Ibutilide.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Ibutilide.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Ibutilide.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Ibutilide.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
LidocaineLidocaine may increase the arrhythmogenic activities of Ibutilide.Approved, Vet Approved
LithiumLithium may increase the QTc-prolonging activities of Ibutilide.Approved
LopinavirIbutilide may increase the QTc-prolonging activities of Lopinavir.Approved
LumefantrineIbutilide may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Ibutilide.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Ibutilide.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Ibutilide.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Ibutilide.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ibutilide.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Ibutilide.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Ibutilide.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Ibutilide.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
NelfinavirNelfinavir may increase the QTc-prolonging activities of Ibutilide.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Ibutilide.Approved
NilotinibIbutilide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Ibutilide.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ibutilide.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Ibutilide.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
PaliperidoneIbutilide may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Ibutilide.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Ibutilide.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Ibutilide.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Ibutilide.Approved
PimozideIbutilide may increase the QTc-prolonging activities of Pimozide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Ibutilide.Approved
ProcainamideIbutilide may increase the QTc-prolonging activities of Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Ibutilide.Approved
PropafenonePropafenone may increase the arrhythmogenic activities of Ibutilide.Approved
PropofolPropofol may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Ibutilide.Approved
QuetiapineIbutilide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineIbutilide may increase the QTc-prolonging activities of Quinidine.Approved
QuinineIbutilide may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ibutilide.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Ibutilide.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Ibutilide.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ibutilide.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
SotalolIbutilide may increase the QTc-prolonging activities of Sotalol.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ibutilide.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Ibutilide.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Ibutilide.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Ibutilide.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ibutilide.Approved
TetrabenazineIbutilide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineIbutilide may increase the QTc-prolonging activities of Thioridazine.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ibutilide.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Ibutilide.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
ToremifeneIbutilide may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Ibutilide.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ibutilide.Approved, Vet Approved
VandetanibIbutilide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Ibutilide.Approved
VemurafenibIbutilide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Ibutilide.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Ibutilide.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Ibutilide.Approved, Investigational
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Ibutilide.Approved
ZuclopenthixolIbutilide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US5155268A
General References
Not Available
External Links
Human Metabolome Database
HMDB14453
KEGG Drug
D00648
KEGG Compound
C07753
PubChem Compound
60753
PubChem Substance
46507904
ChemSpider
54755
BindingDB
50131432
ChEBI
5856
ChEMBL
CHEMBL533
Therapeutic Targets Database
DAP000279
PharmGKB
PA449958
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibutilide
ATC Codes
C01BD05 — Ibutilide
AHFS Codes
  • 24:04.04.20
PDB Entries
Not Available
FDA label
Download (878 KB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionProlonged QT Interval in EKG and Sudden Death1
4CompletedTreatmentNonvalvular Atrial Fibrillation1
4RecruitingPreventionDrug-induced QT Interval Prolongation / Prolonged QT Interval in EKG and Sudden Death1
Not AvailableCompletedTreatmentPersistent Atrial Fibrillation1
Not AvailableUnknown StatusBasic ScienceNonvalvular Atrial Fibrillation / Pulmonary Vein Ablation1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
  • Bioniche pharma usa llc
  • Pharmaforce inc
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous0.1 mg
Injection, solutionIntravenous.1 mg/mL
Prices
Unit descriptionCostUnit
Corvert 1 mg/10 ml vial54.27USD ml
Ibutilide fum 1 mg/10 ml vial33.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5155268 No1992-12-282009-12-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility100 mg/mLNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00473 mg/mLALOGPS
logP4.72ALOGPS
logP2.54ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)9.72ChemAxon
pKa (Strongest Basic)10.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area69.64 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity109.18 m3·mol-1ChemAxon
Polarizability46.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9363
Caco-2 permeable-0.6669
P-glycoprotein substrateSubstrate0.6142
P-glycoprotein inhibitor INon-inhibitor0.7689
P-glycoprotein inhibitor IINon-inhibitor0.8893
Renal organic cation transporterNon-inhibitor0.8738
CYP450 2C9 substrateNon-substrate0.8131
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5472
CYP450 1A2 substrateNon-inhibitor0.7721
CYP450 2C9 inhibitorNon-inhibitor0.8256
CYP450 2D6 inhibitorNon-inhibitor0.8114
CYP450 2C19 inhibitorNon-inhibitor0.7115
CYP450 3A4 inhibitorNon-inhibitor0.7974
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8467
Ames testNon AMES toxic0.7092
CarcinogenicityNon-carcinogens0.6799
BiodegradationNot ready biodegradable0.9945
Rat acute toxicity2.5314 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5736
hERG inhibition (predictor II)Inhibitor0.7592
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Benzenoids
Sub Class
Benzene and substituted derivatives
Direct Parent
Phenylbutylamines
Alternative Parents
Sulfanilides / Aralkylamines / Organosulfonamides / Organic sulfonamides / Aminosulfonyl compounds / Trialkylamines / Secondary alcohols / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Phenylbutylamine / Sulfanilide / Aralkylamine / Organic sulfonic acid amide / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Aminosulfonyl compound / Sulfonyl / Secondary alcohol
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organic amino compound, benzenes (CHEBI:5856 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Activator
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB1
Uniprot ID
Q02641
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
65712.995 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J: Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol. 2004 Aug;66(2):240-9. [PubMed:15266014 ]
  2. Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, Sutcliffe MJ, Mitcheson JS: Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol. 2006 Feb;69(2):509-19. Epub 2005 Nov 16. [PubMed:16291873 ]
  3. Wolpert C, Schimpf R, Veltmann C, Borggrefe M: [Short QT syndrome]. Herz. 2007 May;32(3):206-10. [PubMed:17497253 ]
  4. Wolpert C, Schimpf R, Veltmann C, Giustetto C, Gaita F, Borggrefe M: Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):611-7. [PubMed:16076272 ]
  5. Yang T, Snyders D, Roden DM: Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001 Nov;38(5):737-44. [PubMed:11602820 ]
  6. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Voltage-gated calcium channel activity
Specific Function
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
Gene Name
CACNG1
Uniprot ID
Q06432
Uniprot Name
Voltage-dependent calcium channel gamma-1 subunit
Molecular Weight
25028.105 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium channel activity
Specific Function
Ion channel that contributes to passive transmembrane potassium transport and to the regulation of the resting membrane potential in brain astrocytes, but also in kidney and in other tissues (PubMe...
Gene Name
KCNK1
Uniprot ID
O00180
Uniprot Name
Potassium channel subfamily K member 1
Molecular Weight
38142.775 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Potassium ion leak channel activity
Specific Function
Exhibits outward rectification in a physiological K(+) gradient and mild inward rectification in symmetrical K(+) conditions.
Gene Name
KCNK6
Uniprot ID
Q9Y257
Uniprot Name
Potassium channel subfamily K member 6
Molecular Weight
33746.8 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH6
Uniprot ID
Q9H252
Uniprot Name
Potassium voltage-gated channel subfamily H member 6
Molecular Weight
109923.705 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH7
Uniprot ID
Q9NS40
Uniprot Name
Potassium voltage-gated channel subfamily H member 7
Molecular Weight
134998.525 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...
Gene Name
KCNJ11
Uniprot ID
Q14654
Uniprot Name
ATP-sensitive inward rectifier potassium channel 11
Molecular Weight
43540.375 Da
References
  1. Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69. [PubMed:15926871 ]
  2. Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30. [PubMed:9257085 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:34